Methods: A Opaganib datasheet note based retrospective review of 18 patients who had early exposure to PI at Kings College Hospital, LondonPopulation: The mean age was 53.6 (43–73) years. All the patients had experienced treatment failure

with standard therapy. 88.9% of the patients were cirrhotic, with histological confirmation in 50%. There was equal numbers of A and B subtype patients (41.2%) the rest being A/B. For IL28B polymorphisms 27.8% were CC, 61.1% CT and 11.1% were TT. 61.1% were responder relapsers, 22.2% were partial responders, 16.7% null-responders. The mean platelet count was at baseline was 147.8 (58–343) ×109/L, with 33% having a platelet count less than 10 0 × 109/L. All patients were planned for 48 weeks therapy given that all had previous treatment. 44.4% received therapy with Telaprevir and 55.5% had Boceprevir based regime. Results: 61.1% of patients completed 48 weeks of therapy. Reasons for early termination included; 22.2% stopping because of viral breakthrough, 11.1% for hepatic

decompensation and 5.6% for acute pancreatitis. The 61.1% of patients that completed 48 weeks therapy all had an end of treatment Fluorouracil solubility dmso respons. SVR was achieved in 44.4% of patients, of those who achieved end of treatment response but no SVR, one patient was lost to follow up, one had late viral breakthrough and one has not yet reached the 24 week post treatment mark. Conclusion: In

our small monocentric cohort of complex patients reasonable SVR rates were achieved with use of protease inhibitors in an expert environment. Key Word(s): 1. Real world; 2. genotype 1 HCV; 3. protease inhibitor; 4. difficult to-treat; Presenting Author: TAUFIQUE AHMED Additional Authors: ASHLEY BARNABAS, SARAH KNIGHTON, KATHRYN OAKES, AISLING CONSIDINE, ABID SUDDLE, KOSH AGARWAL Corresponding Author: TAUFIQUE AHMED Affiliations: selleck Khoo Teck Puat Hospital; Kings College Hospital NHS Foundation Trust Objective: To delineate adverse events (AEs) in difficult to treat (DTT) HCV patients treated with protease inhibitor triple therapy. Methods: A retrospective case review of all patients completing antiviral therapy at Kings College Hospital. Results: 26 patients had complete data. 84.6% were treatment experienced with 84% cirrhotic. Equal numbers of patients were treated with each protease inhibitor. During treatment 26.9% patients had a lowest recorded haemoglobin of <8 g/dL with a mean drop from baseline of 4.7 (1.9–7.2) g/dL. 46.2% required Erythropoietin, 19.2% required blood transfusion and 50% required Ribavirin dose reduction. 42.3% of patients had a lowest recorded neutrophil count < 1 cells/ml, with a mean drop from baseline of 2.11 (0.17–5.31) cells/ml and 19.2% required G-CSF. 34.